Intravitreal Injectables Market - Growth, Future Prospects and Competitive Analysis, 2022

The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2022 to 2030. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment.

Rising prevalence of diabetes and increasing geriatric population drive macular degeneration market growth

As per the research citing of the Lancet journal the global prevalence rate of any age related macular degeneration is 8.69% with a higher prevalence rate in the Caucasian population followed by mongoloids. The primary factors that increase the risk factor for occurrence of macular degeneration are increasing geriatric population, smoking, obesity, genetic, diabetes etc. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people having previous history of diabetes. Endophthalmitis is growing at faster rate owing to rise in air and water pollution and eye trauma.

Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market

Anti-VEGF is dominating the drug class segment for Intravitreal injections market. Since its commercialization in 2006 drugs such as bevacizumab (Avastin), ranibizumab (Lucentis) etc. are considered as the first line drug therapy in patients suffering with neovascular age related macular degeneration and ocular vein occlusion. Its inherent features such as excellent biocompatibility and impressive pharmacodynamic properties has led to its increased popularity among ophthalmologist worldwide. Corticosteroids are used as an adjuvant drug therapy in alleviating inflammation caused due to eye infections. Antifungal drugs and antibiotics together are prescribed in eye infections such as endophthalmitis and retinitis.

Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth

In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffering with low vision. Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America. Europe represents 26% share on account of the presence of thriving healthcare infrastructure and domicile of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F.Hoffman-La Roche Ltd. etc. propel the market growth in Europe. Asia Pacific is holding 20% market share and is keen to capture the regional market in the near future on account of supportive regulatory environment provided by healthcare agencies and developing ophthalmic research centers providing optimum eye care.

Pharmaceutical giants competing to maintain stronghold in intravitreal injectables market are: Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Intravitreal Injectables market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Intravitreal Injectables market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Indication

Macular Degeneration
Diabetic Retinopathy
Retinal Vein Occlusions
Endophthalmitis
Others

Drug Class

Anti-VEGF
Corticosteroids
Antibiotics
Antivirals
Antifungals

Region Segment (2020-2030; US$ Million)

North America
- U.S.
- Canada
- Rest of North America

UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe

Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

Latin America
- Brazil
- Mexico
- Rest of Latin America

Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation
Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Intravitreal Injectables market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Intravitreal Injectables market?

Which is the largest regional market for Intravitreal Injectables market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Intravitreal Injectables market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Intravitreal Injectables market worldwide?

Product Code: 138657-08-22

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Intravitreal Injectables Market
2.2. Global Intravitreal Injectables Market, By Indication, 2021 (US$ Million)
2.3. Global Intravitreal Injectables Market, By Drug Class, 2021 (US$ Million)
2.4. Global Intravitreal Injectables Market, By Geography, 2021 (US$ Million)
2.5. Impact of Covid 19
2.6. Attractive Investment Proposition by Geography, 2021
2.7. Competitive Analysis
- 2.7.1. Market Positioning of Key Intravitreal Injectables Market Vendors
- 2.7.2. Strategies Adopted by Intravitreal Injectables Market Vendors
- 2.7.3. Key Industry Strategies

3. Intravitreal Injectables Market: Business Outlook & Market Dynamics

3.1. Introduction
3.2. Global Intravitreal Injectables Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape

4. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)

4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
- 4.3.1. Macular Degeneration
- 4.3.2. Diabetic Retinopathy
- 4.3.3. Retinal Vein Occlusions
- 4.3.4. Endophthalmitis
- 4.3.5. Others

5. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
- 5.3.1. Anti-VEGF
- 5.3.2. Corticosteroids
- 5.3.3. Antibiotics
- 5.3.4. Antivirals
- 5.3.5. Antifungals

6. North America Intravitreal Injectables Market, 2020-2030, USD (Million)

6.1. Market Overview
6.2. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)
6.3. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)
6.4.Intravitreal Injectables Market: By Region, 2020-2030, USD (Million)
- 6.4.1.North America
  - 6.4.1.1. U.S.
  - 6.4.1.2. Canada
  - 6.4.1.3. Rest of North America

7. UK and European Union Intravitreal Injectables Market, 2020-2030, USD (Million)

7.1. Market Overview
7.2. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)
7.3. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)
7.4.Intravitreal Injectables Market: By Region, 2020-2030, USD (Million)
- 7.4.1.UK and European Union
  - 7.4.1.1. UK
  - 7.4.1.2. Germany
  - 7.4.1.3. Spain
  - 7.4.1.4. Italy
  - 7.4.1.5. France
  - 7.4.1.6. Rest of Europe

8. Asia Pacific Intravitreal Injectables Market, 2020-2030, USD (Million)

8.1. Market Overview
8.2. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)
8.3. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)
8.4.Intravitreal Injectables Market: By Region, 2020-2030, USD (Million)
- 8.4.1.Asia Pacific
  - 8.4.1.1. China
  - 8.4.1.2. Japan
  - 8.4.1.3. India
  - 8.4.1.4. Australia
  - 8.4.1.5. South Korea
  - 8.4.1.6. Rest of Asia Pacific

9. Latin America Intravitreal Injectables Market, 2020-2030, USD (Million)

9.1. Market Overview
9.2. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)
9.3. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)
9.4.Intravitreal Injectables Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Latin America
  - 9.4.1.1. Brazil
  - 9.4.1.2. Mexico
  - 9.4.1.3. Rest of Latin America

10. Middle East and Africa Intravitreal Injectables Market, 2020-2030, USD (Million)

10.1. Market Overview
10.2. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)
10.3. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)
10.4.Intravitreal Injectables Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Middle East and Africa
  - 10.4.1.1. GCC
  - 10.4.1.2. Africa
  - 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

11.1. Allergan, Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
11.2. Alimera Sciences
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
11.3. Bristol-Myers Squibb Company
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
11.4. Eyetech, Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
11.5. F. Hoffmann-La Roche Ltd
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
11.6. Genentech, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Initiatives
11.7. Novartis AG
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Initiatives
11.8. Regeneron Pharmaceuticals, Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Initiatives
11.9. ThromboGenics, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Initiatives
11.10. Valeant Pharmaceuticals International, Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Initiatives

Product Code: 138657-08-22

List of Tables

TABLE 1 Global Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 2 Global Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)
TABLE 3 North America Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 4 North America Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)
TABLE 5 UK and European Union Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 6 UK and European Union Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)
TABLE 7 Asia Pacific Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 8 Asia Pacific Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)
TABLE 9 Latin America Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 10 Latin America Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)
TABLE 11 Middle East and Africa Intravitreal Injectables Market By Indication, 2020-2030, USD (Million)
TABLE 12 Middle East and Africa Intravitreal Injectables Market By Drug Class, 2020-2030, USD (Million)

List of Figures

FIG. 1 Global Intravitreal Injectables Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Intravitreal Injectables Market: Quality Assurance
FIG. 5 Global Intravitreal Injectables Market, By Indication, 2021
FIG. 6 Global Intravitreal Injectables Market, By Drug Class, 2021
FIG. 7 Global Intravitreal Injectables Market, By Geography, 2021
FIG. 8 Global Intravitreal Injectables Market, By Indication, 2021 Vs 2030, %
FIG. 9 Global Intravitreal Injectables Market, By Drug Class, 2021 Vs 2030, %
FIG. 10 U.S. Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 11 Canada Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 12 Rest of North America Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 13 UK Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 14 Germany Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 15 Spain Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 16 Italy Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 17 France Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 18 Rest of Europe Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 19 China Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 20 Japan Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 21 India Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 22 Australia Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 23 South Korea Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 24 Rest of Asia Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 25 Brazil Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 26 Mexico Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 27 Rest of Latin America Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 28 GCC Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 29 Africa Intravitreal Injectables Market (US$ Million), 2020 - 2030
FIG. 30 Rest of Middle East and Africa Intravitreal Injectables Market (US$ Million), 2020 - 2030

Intravitreal Injectables Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

Description

Table of Contents

List of Tables

Industry Outlook

Rising prevalence of diabetes and increasing geriatric population drive macular degeneration market growth

Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market

Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth

Historical & Forecast Period

Research Methodology

Geographical revenues generate by countries considered in the report:

Market Segmentation

Indication

Drug Class

Region Segment (2020-2030; US$ Million)

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Key questions answered in this report:

Table of Contents

1. Preface

2. Executive Summary

3. Intravitreal Injectables Market: Business Outlook & Market Dynamics

4. Intravitreal Injectables Market: By Indication, 2020-2030, USD (Million)

5. Intravitreal Injectables Market: By Drug Class, 2020-2030, USD (Million)

6. North America Intravitreal Injectables Market, 2020-2030, USD (Million)

7. UK and European Union Intravitreal Injectables Market, 2020-2030, USD (Million)

8. Asia Pacific Intravitreal Injectables Market, 2020-2030, USD (Million)

9. Latin America Intravitreal Injectables Market, 2020-2030, USD (Million)

10. Middle East and Africa Intravitreal Injectables Market, 2020-2030, USD (Million)

11. Company Profile

List of Tables

List of Figures